Tenderwize
Wróć do wyszukiwania

Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 186 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

60/100

Ocena szansy

PromisingLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

20 / 100

Czynniki ryzyka

The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...

Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Pharmaceutical discount contract for Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
  • Supply of the drug under uniform conditions set by TK
Pokaż pełne podsumowanie

Open House procedure by Techniker Krankenkasse (TK) for discount contracts on the drug Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) under §130c SGB V. The procedure allows continuous joining during the contract term (max 24 months from March 2025 to February 2027). No estimated value provided; no competition or award criteria; eligibility requires being a pharmaceutical entrepreneur with authorization for the drug. Submission is by email (with qualified electronic signature) or post. Documents are available but were not analyzed.

Ryzyka

The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...

Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drug
  • Must have a valid marketing authorization for the drug in Germany or be otherwise entitled to market it

Eligibility

  • Must provide a self-declaration confirming eligibility and no exclusion grounds

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria specified; contract is awarded to all eligible participants who meet requirements.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

Discount contracts for the combination drug Bictegravir/Emtricitabin/Tenofoviralafenamid. Continuous enrollment; no exclusivity; standard conditions.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Feb 2025 - Feb 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified; contract is awarded to all eligible participants who meet requirements.

Termin

Deadline Feb 27, 2027

Szczegóły zamówienia

Data publikacji
19 Jan 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
39458-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3